We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag
Read MoreHide Full Article
Harpoon Therapeutics, Inc. announced that the FDA has granted Orphan Drug designation toHPN217 for the treatment of multiple myeloma.
Notably, the Orphan Drug designation is granted to drugs that are capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses, an exemption from the FDA user fee and seven-year marketing exclusivity following approval.
Shares of the company have surged 44.2% in the past year against the industry’s decline of 2.6%.
HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC), targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. The candidate is in a phase I/II dose-escalation study for the potential treatment of relapsed/refractory multiple myeloma (RRMM). It expects to present interim data from the study later in 2021.
There are many other companies developing candidates for the treatment of RRMM. In December 2020, Johnson & Johnson (JNJ - Free Report) initiated the rolling submission of its biologics license application (BLA) to the FDA for its BCMA CAR-T therapy, ciltacabtagene autoleucel (cilta-cel), being developed for the treatment of adult patients with RRMM.
bluebird bio (BLUE - Free Report) and Bristol Myers’ (BMY - Free Report) investigational BCMA-directed CAR-T therapy, idecabtagene vicleucel (ide-cel), has also been developed for RRMM. The The FDA has set an action date of Mar 27, 2021 for the candidate.
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag
Harpoon Therapeutics, Inc. announced that the FDA has granted Orphan Drug designation toHPN217 for the treatment of multiple myeloma.
Notably, the Orphan Drug designation is granted to drugs that are capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses, an exemption from the FDA user fee and seven-year marketing exclusivity following approval.
Shares of the company have surged 44.2% in the past year against the industry’s decline of 2.6%.
HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC), targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. The candidate is in a phase I/II dose-escalation study for the potential treatment of relapsed/refractory multiple myeloma (RRMM). It expects to present interim data from the study later in 2021.
There are many other companies developing candidates for the treatment of RRMM. In December 2020, Johnson & Johnson (JNJ - Free Report) initiated the rolling submission of its biologics license application (BLA) to the FDA for its BCMA CAR-T therapy, ciltacabtagene autoleucel (cilta-cel), being developed for the treatment of adult patients with RRMM.
bluebird bio (BLUE - Free Report) and Bristol Myers’ (BMY - Free Report) investigational BCMA-directed CAR-T therapy, idecabtagene vicleucel (ide-cel), has also been developed for RRMM. The The FDA has set an action date of Mar 27, 2021 for the candidate.
Harpoon currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>